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Over the past two decades the Human Papillomavirus (HPV)
ﬁeld has expanded to include a full spectrum of researchers and
practitioners from previously distant disciplines. This expansion
has led to the development of a truly transdisciplinary group of
scientists focused on advancing our understanding of HPV and
implementing best practices to eliminate HPV related diseases.
Currently the spectrum of PV research ranges from basic viral
pathogenesis to global health policy, such as international public
health programs, health systems organization vaccine ﬁnancing
and procurement, through to HPV epidemiology and intervention
trials in HPV vaccination, screening and treatment. The ﬁeld also
has signiﬁcant clinical activity in pathology, gynecology, head and
neck, gastroenterology (anal) and genitourinary (penile) oncology,
as well as in HPV diagnostics and cancer and pre-cancer treat-
ments. Scientists in the ﬁeld have elucidated many of the mechan-
isms by which papillomaviruses infect cells, proceed through their
life cycle and cause cellular transformation, but much remains to
be done such as understanding the basis of persistent HPV
infections. The roots of the ﬁeld remain however, in the areas of
basic molecular biology, PVs taxonomy and phylogenetic evolution
of PVs, as well as in the topics of host and viral immunology.
Collectively this research is leading to the development of novel
immunotherapies and anti-viral treatments, an area that is rapidly
advancing. More recently, the disciplines of communication,
dissemination, and decision-making sciences have assumed larger
prominence as the community begins the daunting task of bring-
ing new and effective technologies to populations worldwide. To
ensure implementation of best practices derived from our collec-
tive research, communication and educational expertise has been
recognized as essential.
The HPV ﬁeld is organizing itself into an established discipline.
We have had a tradition of regular international meetings for over
25 years, typically every one to two years and a scientiﬁc society
for a decade which has now crystallized into a permanent
structure with a formal constitution. Starting in 2015, we will
have a Journal devoted to showcasing cutting-edge research in all
areas related to PV and the challenging emerging research on
polyomaviruses.
Papillomavirus Research (acronym PVR) has been established
with the goal of fostering cross-fertilization of disciplines and
facilitating multidisciplinary research of the highest quality. Ulti-
mately, through this platform PVR seeks to support continued
investigation into basic virology and pathogenesis, as well as
international action in cancer prevention and treatment as a
natural follow up to decades of fertile PV research.
This knowledge has enabled the papillomavirus community to
push the frontiers of cancer prevention to present the world with
highly effective HPV vaccines and HPV testing systems validated
and amenable to the needs of screening programs. These two
achievements dramatically advance our opportunities to control
not only cervical cancer but also a number of other HPV induced
cancers affecting men and women worldwide. Only anti-smoking
programs rival such a broad reach of global cancer prevention
across multiple cancer types. It will also be an ambition of PVR and
the International Papillomavirus Society (IPVS) to advance the
international agenda to include action plans in HPV related cancer
control and to continue the story of success written by so many
colleagues worldwide to improve the longevity and quality of life
of our populations.
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